Organovo cancels merger with Tarveda Therapeutics

Organovo has called off a planned merger with Tarveda Therapeutics after the companies failed to get approval from shareholders.



“I would like to deeply thank Organovo’s team, our Board of Directors, our advisors, and our outstanding counterparts at Tarveda Therapeutics for the months of diligent effort and well-intentioned negotiations... We continue to believe that Tarveda is an exciting and innovative company, and we wish them much success in their on-going mission to bring significant advancements to the treatment of a broad range of patients suffering from solid tumor malignancies.”
Taylor J. Crouch, CEO Organovo

The failure of the deal to get shareholder approval comes after the Organovo founder issued a letter skewering the company’s board and criticizing the deal.

The_MergerSight_Group_Instagram
The_MergerSight_Group_LinkedIn
The_MergerSight_Group_Facebook

© 2018 - 2020 The MergerSight Group

Subscribe to Newsletter